SOURCE: Oxford Biomedica Plc

October 06, 2006 02:02 ET

Oxford Biomedica Plc announces Presentation at Conference

OXFORD, UK -- (MARKET WIRE) -- October 6, 2006 --

For immediate release                                      6 OCTOBER 2006


                                Oxford BioMedica

OXFORD BIOMEDICA PRESENTS ENCOURAGING IMMUNOLOGICAL DATA FROM SIX PHASE II
                     TRIALS OF TROVAX(R) IN VARIOUS CANCERS

        - TroVax induces significant anti-cancer immune responses -

Oxford, UK - 6 October 2006: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that it has presented further encouraging data from six Phase II trials of TroVax, its lead cancer immunotherapy product, at the 14th International Cancer Immunotherapy Meeting, which is sponsored by the Cancer Research Institute and the Academy of Cancer Immunology and is being held from 4-6 October 2006, in New York City.

http://www.cancerresearch.org/cancerimmunotherapy2006/index.html

The presentation comprised an analysis of immune responses induced against the 5T4 tumour antigen by TroVax in 63 patients. In addition to immunological data from two completed Phase II trials of TroVax with standard chemotherapy in colorectal cancer, the analysis included new data from four ongoing Phase II trials of TroVax alongside standard therapies in renal cancer and prostate cancer. The results showed that 84% of patients had 5T4-specific antibody responses after three injections of TroVax. 5T4-specific cellular responses were evident in 87% of patients in the two trials in colorectal cancer, and preliminary analyses also show cellular responses in the renal cancer and prostate cancer trials. These data demonstrate that TroVax can be administered both safely and also without loss of immunological efficacy in these three types of cancer alongside numerous co-medications.

Dr Mike McDonald, Oxford BioMedica's Chief Medical Officer, commented on the immunological analysis: "Stimulating a significant and sustainable anti-cancer immune response has been a challenge for the field of cancer immunotherapy. TroVax has been shown to induce consistently strong immune responses in multiple cancer settings even when administered alongside other therapies. These data confirm the breadth of potential application for TroVax and increase our confidence in its therapeutic effect as we start Phase III development."

                                  -Ends-



For further information, please contact:

Oxford BioMedica plc:
Professor Alan Kingsman, Chief Executive         Tel: +44 (0)1865 783 000

City/Financial Enquiries:
Lisa Baderoon/ Mark Court/ Mary-Jane Johnson 
Buchanan Communications                          Tel: +44 (0)20 7466 5000

Scientific/Trade Press Enquiries:
Gemma Bradley/ Susan Yu/ Katja Stout             Tel: +44 (0)20 3008 7550
Northbank Communications

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.

Oxford BioMedica has core expertise in gene delivery, as well as in-house clinical, regulatory and manufacturing know-how. In oncology, the pipeline includes two clinical candidates and a preclinical targeted antibody therapy, which is being developed in collaboration with Wyeth. The Company has started Phase III development of its lead cancer immunotherapy product, TroVax, in renal cancer and multiple Phase II trials in various cancer settings are ongoing or planned. In neurotherapy, the Company's lead product, ProSavin, is expected to enter clinical trials in Parkinson's disease in 2007. The preclinical pipeline includes gene-based products for vision loss, motor neuron disease and nerve repair.

The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 70 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Oxford BioMedica has corporate collaborations with Wyeth, Intervet, Sigma-Aldrich, Viragen, MolMed, Virxsys and Kiadis; and has licensed technology to a number of companies including Merck & Co, Biogen Idec and Pfizer.

Further information is available at www.oxfordbiomedica.co.uk

2. TroVax®

TroVax is Oxford BioMedica's leading cancer immunotherapy product. It is designed specifically to stimulate an anti-cancer immune response and has potential application in most solid tumour types. TroVax targets the tumour antigen 5T4, which is broadly distributed throughout a wide range of solid tumours. The presence of 5T4 is correlated with poor prognosis. The product consists of a poxvirus (MVA) gene transfer system, which delivers the gene for 5T4 and stimulates a patient's body to produce an anti-5T4 immune response. This immune response destroys tumour cells carrying the 5T4. TroVax has attracted external support from Cancer Research UK, the US National Cancer Institute and the UK clinical trials network, QUASAR. Over 150 patients have now been treated with TroVax in ten clinical trials (collectively over 500 doses). The Company is targeting colorectal cancer and renal cell carcinoma as lead indications for the development of TroVax. Renal cell carcinoma is an indication where TroVax might achieve a rapid route to product registration. Oxford BioMedica is starting a Phase III trial (TRIST - TroVax Renal Immunotherapy Survival Trial) in 700 patients with advanced renal cell carcinoma in the second half of 2006. The TRIST study received a Special Protocol Assessment from the US Food and Drug Administration in May 2006. A Phase II trial in prostate cancer is ongoing and a trial in breast cancer is due to start under the auspices of the US Southwest Oncology Group.

                     This information is provided by RNS
           The company news service from the London Stock Exchange